S-1/A: FibroBiologics Eyes $20 Million in Unit Offering to Fuel Cell Therapy Development

FibroBiologics is launching a best-efforts offering of up to 1,801,801 units, each comprising a share of common stock and a warrant, to raise capital for research, development, and general corporate purposes.

Summary

• FibroBiologics, Inc. is undertaking an offering of up to 1,801,801 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, aiming to raise approximately $20 million before expenses.
• The offering is on a 'best efforts' basis, meaning there's no guarantee all units will be sold.
• The assumed public offering price is $11.10 per unit, based on the last reported sale price of the common stock on April 23, 2024.
• Warrants have an exercise price of $11.10 and are exercisable for five years.
• The company intends to use the net proceeds for general corporate purposes, including hiring personnel, research and development, and working capital.
• Maxim Group LLC is acting as the exclusive placement agent for the offering.
• The offering is expected to terminate on May 31, 2024, unless fully subscribed or terminated earlier.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 5

Explanation: The document is neutral. It outlines the terms of a stock offering, potential risks, and future plans. The company's financial situation and the speculative nature of biopharmaceutical development contribute to a balanced outlook.

Positives

• The company has a pipeline of product candidates at various stages of development.
• The company has an experienced leadership team with successful track records in entrepreneurial startup companies and the life sciences industry.
• The company has a board of directors with life sciences operational leadership experience.
• The company has a world-renowned scientific advisory board with relevant expertise.
• The company has an intellectual property portfolio includes 48 issued patents and 108 pending patents for the use of fibroblasts in diverse therapeutic areas.

Negatives

• The offering is on a 'best efforts' basis, meaning there's no guarantee all units will be sold.
• Investors will experience immediate dilution as a result of this offering.
• There is no public market for the warrants in this offering, which may limit your ability to resell the warrants.
• The market price of our common stock may never exceed the exercise price of the warrants issued in connection with this offering.
• There is substantial doubt about our ability to continue as a going concern.

Risks

• The successful development of biopharmaceutical products is highly uncertain.
• The company has a limited operating history and none of its current product candidates have been approved for commercial sale.
• The company has incurred significant net losses since inception, expect to continue to incur significant net losses for the foreseeable future and may never achieve or maintain profitability.
• The company will require substantial additional capital to finance its operations.
• The regulatory approval processes of the FDA, the EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.
• The company may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of its product candidates.
• The outcome of preclinical studies or early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, the EMA or other comparable foreign regulatory authorities.
• The company's current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
• Even if approved, the company's product candidates may not achieve adequate market acceptance.
• The company faces significant competition.

Future Outlook

The company believes its existing capital will fund operations through at least February 28, 2025, and plans to raise additional capital through equity offerings, debt financings, collaborations, and licensing arrangements.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates.

Related Party Transactions

• In May 2021, the company issued Series A Preferred Stock to FibroGenesis in exchange for intellectual property rights.
• In July 2022, the company loaned $300,000 to FibroGenesis at 0% interest and one year maturity date.
• In October 2022, the company loaned an additional $60,000 to FibroGenesis at 0% interest and one year maturity.
• In January 2023, the company entered into an Agreement Regarding Right of First Negotiation with FibroGenesis, or the ROFN Agreement.
• In December 2021, the company issued and sold to investors, some of whom hold more than 5% shares, in a private placement $1.3 million of our convertible promissory notes, or the 2021 Notes.
• In January 2022 and April 2022, the company issued and sold to investors, some of whom hold more than 5% of shares, in a private placement $0.35 million and $3.95 million, respectively, of our convertible promissory notes, or the 2022 Notes.

Stakeholder Impact

• The offering will dilute existing shareholders.
• The success of the offering will impact the company's ability to fund research and development, potentially affecting future product development and commercialization.
• The company's ability to attract and retain key personnel may be affected by the company's financial performance and stock price.

Next Steps

• Complete pre-clinical studies for CYWC628 in Q3 2024.
• Initiate a Phase 1/2 clinical trial in Australia for treatment of diabetic foot ulcers in 2025 with results expected in the third quarter of 2025.
• Complete a technology transfer of cell manufacturing processes to a CDMO and conduct feasibility studies for our fibroblast spheroid-based drug product, with the intent to enter into a master services agreement with that CDMO to supply drug product for clinical trials.
• Produce a master cell bank, working cell bank, and drug product for use in clinical trials by year end 2024.

Key Dates

Keywords

FibroBiologics, cell therapy, warrants, common stock, offering, fibroblasts, clinical trials, biologics, Maxim Group, regulatory approval